GlassScriptPhysician profile
Kerrie Grunnet Satcher
NPI 1912432659
$4,000.52
in general payments reported to CMS, 2019-2025
23 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $135 · 2022: $450 · 2023: $1,097 · 2024: $1,045 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,253 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,253.49 |
| Education | $162.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $659.85 | 2022-2025 | Dupixent |
| Genzyme Corporation | $659.29 | 2022-2025 | |
| Abbvie INC. | $462.79 | 2022-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $312.43 | 2022-2024 | |
| Janssen Biotech, INC. | $282.21 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $237.47 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $231.07 | 2021-2025 | Opzelura |
| Organon LLC | $160.63 | 2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $150.17 | 2023-2024 | Winlevi, Ilumya |
| Arcutis Biotherapeutics, INC. | $132.20 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $131.75 | 2022-2025 | Adbry |
| Pfizer INC. | $119.50 | 2022-2025 | |
| Ucb, INC. | $91.94 | 2025 | Bimzelx |
| Dermavant Sciences, INC. | $69.45 | 2023 | Vtama |
| Galderma Laboratories, L.P. | $65.80 | 2024-2025 | Nemluvio |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $58.63 | 2023-2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $47.55 | 2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.38 | 2022-2025 | Spevigo |
| Pierre Fabre Pharmaceuticals, INC. | $30.51 | 2025 | Hemangeol |
| Verrica Pharmaceuticals INC. | $22.31 | 2023 | Ycanth |
| Springworks Therapeutics, INC. | $16.56 | 2025 | Gomekli |
| Genentech USA, INC. | $15.11 | 2023 | Actemra |
| Strata Skin Sciences, INC. | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerrie Satcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.